FREDERICK, MD--(Marketwired - Dec 12, 2016) - BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com the maker of ActiPatch®, an advanced over-the-counter medical device, announced the publication of a clinical study, An Over-the-counter Central Sensitization Therapy: A Chronic Back Pain Registry Study of Pain Relief, Medication Use & Their Adverse Effects, report which indicates that ActiPatch® Therapy is effective for mitigating chronic back pain and reducing medication use including opioids. This peer reviewed article has been published in the distinguished medical journal of Pain Management, and is available at
ActiPatch Musculoskeletal Pain Therapy is a drug-free, wearable nonprescription medical device that provides 720 hours of flexible on/off therapy for under $30.00 retail, or $.04 per hour.
Chronic pain affects an estimated 1.5 billion people worldwide, with back pain being the most prevalent form. The 7-day ActiPatch registry study of 1,394 back pain sufferers was based in the UK. Baseline pain was 8.04 on a 10-point visual analog scale, or severe pain, with mean pain duration of 6.1 years. High baseline pain was present despite the use of an average 2.5 pain medications per subject, with 71% being prescriptions, including 40% using opiate-based prescription pain medications. More than 60% of the participants reported less than adequate pain relief and 66% experienced adverse side effects from pain medications.
ActiPatch reduced baseline pain, on average, by 39.9%, with 52% experiencing a ≥40% pain reduction averaging 66% from baseline. In addition, 50% of the subjects were able to reduce or eliminate analgesic medication use including those using opiate-based medications.
"In this study group, the use of ActiPatch® not only reduced pain for the majority of individuals but had the added benefit of reducing analgesic medication use and improving overall quality of life in just 7 days," said Ian Rawe, Ph.D., Director of Clinical Research, BioElectronics Corporation. "Therefore we believe these results have important implications for the future of pain management."
BioElectronics has collected data from a total of 12,390 assessments over a two year period from subjects who trialed ActiPatch® in the UK with consistent results. A prior registry study of 5000 general chronic pain subjects was previously published - A UK registry study of the effectiveness of a new over-the-counter chronic pain therapy, Pain Manag. 2015 Nov; 5(6): 413-23, http://www.futuremedicine.com/doi/pdf/10.2217/pmt.15.35
These study results are included in the data BioElectronics has submitted to the FDA for its additional indication of use for nonprescription market clearance for the treatment of musculoskeletal pain.
About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; and Allay® Menstrual Pain Therapy. For more information, please visit www.bielcorp.com.